Naples, FL – April 21, 2025 – TB006, a new investigational drug, has been approved by the US Food and Drug Administration (FDA) for compassionate use and is currently being evaluated in a clinical trial for Alzheimer’s disease. The FDA’s compassionate use designation allows patients with serious or life-threatening conditions to access investigational treatments when no satisfactory alternatives are available.
TB006 is currently undergoing clinical trials to assess its safety and potential effects on inflammation and cognitive function in individuals diagnosed with Alzheimer’s disease. According to clinical investigators involved in early-stage research, the drug has been administered to over 300 patients to date, with no adverse side effects reported.
Preliminary data from a placebo-controlled trial suggested that:
Nearly half of those who took TB006 for at least 3 months showed signs of disease reversal and cognitive improvement
Those who took TB006 had lower levels of inflammation. Reducing inflammation is very important because inflammation is a major cause of Alzheimer’s disease.
These findings are currently being further investigated through ongoing clinical studies. With Alzheimer’s disease on the rise, this is very exciting news for those over age 65 and those with a history of dementia in their family.
Among the clinical sites authorized to provide TB006 under compassionate use is Brain Power Clinics, located in West Palm Beach, Florida. The clinic is led by Dr. Joshua Helman, a Harvard-trained physician with over a decade of experience focused on integrative approaches to cognitive decline. Known to patients as Dr. Josh, he currently administers TB006 under FDA protocols as part of a broader, individualized care model.
Dr. Helman works in partnership with Dr. Robert Love, Ph.D., a neuroscientist recognized for his contributions to the field of Alzheimer’s prevention and brain health. Together, the team at Brain Power Clinics offers a multidisciplinary approach that combines investigational therapies like TB006 with behavioral coaching and lifestyle interventions designed to support cognitive function.
Participation in the compassionate use program is limited to individuals who meet specific eligibility criteria, which include age and diagnosis parameters in accordance with FDA and clinical trial guidelines.
To learn more about working with Dr. Josh in his medical clinic, please text “Memory” to 561-725-3319 or visit www.BrainPowerClinics.com.
Disclaimer: The expert opinions presented in this PR/Story are based on the extensive experience and knowledge of the source company. These views do not necessarily reflect the opinions of the news distribution company and its distribution partners. There is no offer to sell, no solicitation of an offer to buy, and no recommendation of any medical treatment, product, or service in this article. Moreover, nothing contained in this should be construed as medical advice or a recommendation to start, stop, or change any medical treatment or medication. It is your responsibility to determine whether any medical treatment, product, or service is appropriate for you based on your health objectives, medical condition, and risk tolerance. Consult your healthcare provider regarding your specific medical situation. The news distribution company and its distribution partners do not endorse or guarantee the accuracy, completeness, or reliability of the information shared by the guest. Viewers are encouraged to consult with their own healthcare professionals or conduct their own research when making decisions related to medical topics. The source company is the one issuing this release. Please contact them directly for further information.
Media ContactCompany Name: Brain Power ClinicsContact Person: Robert LoveEmail: Send EmailPhone: 305-209-0853Country: United StatesWebsite: http://www.BrainPowerClinics.com/
